CNTB
Connect Biopharma Holdings Ltd
0.8979$
-3.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
Connect Biopharma Holdings Ltd (CNTB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -32 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 19 | Q4 19 | Q1 20 | Q2 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.5 | -6.5 | -26 | 0.0 | 0.0 | -126 | -39 | -146 | -46 | -171 | -53 | -53 | -108 | -44 | -31 | 0.0 | – | -17 | -8.3 | -13 | -16 | -10.0 | -13 | -17 | -11 | -16 | -32 | -77 | |
| 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.7 | 0.2 | 1.3 | 0.4 | 1.6 | 0.5 | 0.5 | 1.8 | 0.5 | 0.5 | 0.0 | – | 0.5 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.7 | |
| 0.3 | 0.3 | – | 0.0 | 0.0 | – | 0.0 | – | 0.0 | – | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | – | 3.1 | 3.3 | 2.0 | 4.9 | 0.9 | 1.0 | 0.9 | 0.9 | 1.2 | 1.5 | 4.6 | |
| – | – | 7.0 | 7.0 | – | 347 | 347 | 21 | 21 | 9.7 | 9.7 | 2.4 | 2.4 | 2.4 | 2.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.2 | 1.2 | – | 0.0 | 0.0 | – | -1.0 | – | 4.2 | – | 5.6 | 5.6 | – | 1.4 | -1.7 | 0.0 | – | 11 | -18 | -2.3 | 2.4 | -0.6 | -0.5 | -1.1 | 2.8 | 2.0 | -0.1 | 3.7 | |
| 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 12 | 7.1 | 0.7 | 0.3 | 5.6 | 1.7 | 1.7 | 1.0 | 2.5 | 0.3 | 0.0 | 0.0 | 0.0 | 0.4 | 0.1 | 0.3 | 0.1 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| -0.2 | -0.2 | 2.2 | 0.0 | 0.0 | -16 | -5.0 | -0.7 | -0.3 | -246 | -246 | -76 | 119 | -6.0 | 34 | – | – | 41 | 12 | – | -16 | – | 5.1 | – | 11 | – | 1.5 | – | |
| – | – | – | – | – | – | 0.0 | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -0.1 | -0.1 | – | -0.2 | -0.2 | -0.2 | -0.2 | -0.3 | -0.3 | -0.5 | -0.5 | -0.5 | -0.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | -0.1 | 0.0 | 0.1 | 659 | 204 | -0.6 | 1.0 | 0.1 | 0.0 | 0.0 | -0.5 | -0.1 | -0.1 | 0.0 | – | -0.1 | 0.1 | 0.0 | 0.3 | 0.0 | 0.2 | 0.2 | 0.7 | 18 | 19 | 38 | |
| -13 | -13 | -22 | 0.0 | 0.1 | 507 | 160 | -159 | -46 | -379 | -126 | -126 | 20 | -63 | 2.0 | 0.0 | – | -82 | 29 | -13 | -32 | -31 | -7.1 | -2.8 | 0.5 | 7.7 | -11 | -5.9 | |
| -6.6 | -6.6 | – | 0.0 | 0.0 | – | -46 | – | -46 | – | -55 | -55 | – | -47 | -31 | 0.0 | – | -17 | -8.4 | -13 | -16 | -10 | -13 | -17 | -11 | -16 | -21 | -65 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.